223 related articles for article (PubMed ID: 28768753)
1.
Kent ST; Rosenson RS; Avery CL; Chen YI; Correa A; Cummings SR; Cupples LA; Cushman M; Evans DS; Gudnason V; Harris TB; Howard G; Irvin MR; Judd SE; Jukema JW; Lange L; Levitan EB; Li X; Liu Y; Post WS; Postmus I; Psaty BM; Rotter JI; Safford MM; Sitlani CM; Smith AV; Stewart JD; Trompet S; Sun F; Vasan RS; Woolley JM; Whitsel EA; Wiggins KL; Wilson JG; Muntner P
Circ Cardiovasc Genet; 2017 Aug; 10(4):e001632. PubMed ID: 28768753
[TBL] [Abstract][Full Text] [Related]
2. PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS).
Mefford MT; Rosenson RS; Cushman M; Farkouh ME; McClure LA; Wadley VG; Irvin MR; Bittner V; Safford MM; Somaratne R; Monda KL; Muntner P; Levitan EB
Circulation; 2018 Mar; 137(12):1260-1269. PubMed ID: 29146683
[TBL] [Abstract][Full Text] [Related]
3. The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy.
Feng Q; Wei WQ; Chung CP; Levinson RT; Bastarache L; Denny JC; Stein CM
Pharmacogenomics J; 2017 Mar; 17(2):204-208. PubMed ID: 26902539
[TBL] [Abstract][Full Text] [Related]
4. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
Cohen JC; Boerwinkle E; Mosley TH; Hobbs HH
N Engl J Med; 2006 Mar; 354(12):1264-72. PubMed ID: 16554528
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study.
Huang CC; Fornage M; Lloyd-Jones DM; Wei GS; Boerwinkle E; Liu K
Circ Cardiovasc Genet; 2009 Aug; 2(4):354-61. PubMed ID: 20031607
[TBL] [Abstract][Full Text] [Related]
6. Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
Lotta LA; Sharp SJ; Burgess S; Perry JRB; Stewart ID; Willems SM; Luan J; Ardanaz E; Arriola L; Balkau B; Boeing H; Deloukas P; Forouhi NG; Franks PW; Grioni S; Kaaks R; Key TJ; Navarro C; Nilsson PM; Overvad K; Palli D; Panico S; Quirós JR; Riboli E; Rolandsson O; Sacerdote C; Salamanca EC; Slimani N; Spijkerman AM; Tjonneland A; Tumino R; van der A DL; van der Schouw YT; McCarthy MI; Barroso I; O'Rahilly S; Savage DB; Sattar N; Langenberg C; Scott RA; Wareham NJ
JAMA; 2016 Oct; 316(13):1383-1391. PubMed ID: 27701660
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke.
Hopewell JC; Malik R; Valdés-Márquez E; Worrall BB; Collins R;
Eur Heart J; 2018 Feb; 39(5):354-359. PubMed ID: 29020353
[TBL] [Abstract][Full Text] [Related]
8. PCSK9 loss-of-function variants and risk of infection and sepsis in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort.
Mitchell KA; Moore JX; Rosenson RS; Irvin R; Guirgis FW; Shapiro N; Safford M; Wang HE
PLoS One; 2019; 14(2):e0210808. PubMed ID: 30726226
[TBL] [Abstract][Full Text] [Related]
9. PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.
Langsted A; Nordestgaard BG; Benn M; Tybjærg-Hansen A; Kamstrup PR
J Clin Endocrinol Metab; 2016 Sep; 101(9):3281-7. PubMed ID: 27218270
[TBL] [Abstract][Full Text] [Related]
10. Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study).
Hallman DM; Srinivasan SR; Chen W; Boerwinkle E; Berenson GS
Am J Cardiol; 2007 Jul; 100(1):69-72. PubMed ID: 17599443
[TBL] [Abstract][Full Text] [Related]
11. The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response.
Ooi TC; Krysa JA; Chaker S; Abujrad H; Mayne J; Henry K; Cousins M; Raymond A; Favreau C; Taljaard M; Chrétien M; Mbikay M; Proctor SD; Vine DF
J Clin Endocrinol Metab; 2017 Sep; 102(9):3452-3460. PubMed ID: 28673045
[TBL] [Abstract][Full Text] [Related]
12. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks.
Peloso GM; Auer PL; Bis JC; Voorman A; Morrison AC; Stitziel NO; Brody JA; Khetarpal SA; Crosby JR; Fornage M; Isaacs A; Jakobsdottir J; Feitosa MF; Davies G; Huffman JE; Manichaikul A; Davis B; Lohman K; Joon AY; Smith AV; Grove ML; Zanoni P; Redon V; Demissie S; Lawson K; Peters U; Carlson C; Jackson RD; Ryckman KK; Mackey RH; Robinson JG; Siscovick DS; Schreiner PJ; Mychaleckyj JC; Pankow JS; Hofman A; Uitterlinden AG; Harris TB; Taylor KD; Stafford JM; Reynolds LM; Marioni RE; Dehghan A; Franco OH; Patel AP; Lu Y; Hindy G; Gottesman O; Bottinger EP; Melander O; Orho-Melander M; Loos RJ; Duga S; Merlini PA; Farrall M; Goel A; Asselta R; Girelli D; Martinelli N; Shah SH; Kraus WE; Li M; Rader DJ; Reilly MP; McPherson R; Watkins H; Ardissino D; ; Zhang Q; Wang J; Tsai MY; Taylor HA; Correa A; Griswold ME; Lange LA; Starr JM; Rudan I; Eiriksdottir G; Launer LJ; Ordovas JM; Levy D; Chen YD; Reiner AP; Hayward C; Polasek O; Deary IJ; Borecki IB; Liu Y; Gudnason V; Wilson JG; van Duijn CM; Kooperberg C; Rich SS; Psaty BM; Rotter JI; O'Donnell CJ; Rice K; Boerwinkle E; Kathiresan S; Cupples LA
Am J Hum Genet; 2014 Feb; 94(2):223-32. PubMed ID: 24507774
[TBL] [Abstract][Full Text] [Related]
13. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
Imran TF; Khan AA; Has P; Jacobson A; Bogin S; Khalid M; Khan A; Kim S; Erqou S; Choudhary G; Aspry K; Wu WC
PLoS One; 2023; 18(12):e0295359. PubMed ID: 38055686
[TBL] [Abstract][Full Text] [Related]
14. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
[TBL] [Abstract][Full Text] [Related]
15. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
Yarmolinsky J; Bull CJ; Vincent EE; Robinson J; Walther A; Smith GD; Lewis SJ; Relton CL; Martin RM
JAMA; 2020 Feb; 323(7):646-655. PubMed ID: 32068819
[TBL] [Abstract][Full Text] [Related]
16. Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease.
Folsom AR; Peacock JM; Boerwinkle E;
Atherosclerosis; 2009 Jan; 202(1):211-5. PubMed ID: 18436227
[TBL] [Abstract][Full Text] [Related]
17. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
[TBL] [Abstract][Full Text] [Related]
18. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.
Ference BA; Robinson JG; Brook RD; Catapano AL; Chapman MJ; Neff DR; Voros S; Giugliano RP; Davey Smith G; Fazio S; Sabatine MS
N Engl J Med; 2016 Dec; 375(22):2144-2153. PubMed ID: 27959767
[TBL] [Abstract][Full Text] [Related]
19. Protective lipid-lowering variants in healthy older individuals without coronary heart disease.
Lacaze P; Riaz M; Sebra R; Hooper AJ; Pang J; Tiller J; Polekhina G; Tonkin A; Reid C; Zoungas S; Murray AM; Nicholls S; Watts G; Schadt E; McNeil JJ
Open Heart; 2021 Jul; 8(2):. PubMed ID: 34341098
[TBL] [Abstract][Full Text] [Related]
20. Loss-of-Function PCSK9 Mutations Are Not Associated With Alzheimer Disease.
Paquette M; Saavedra YGL; Poirier J; Théroux L; Dea D; Baass A; Dufour R
J Geriatr Psychiatry Neurol; 2018 Mar; 31(2):90-96. PubMed ID: 29562810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
